[
    [
        {
            "time": "",
            "original_text": "人金融·创新药指数涨0.94% | 腾盛博药中和抗体更大市场在海外 正在研究用于预防新冠",
            "features": {
                "keywords": [
                    "创新药指数",
                    "腾盛博药",
                    "中和抗体",
                    "新冠预防"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人金融·创新药指数涨0.94% | 腾盛博药中和抗体更大市场在海外 正在研究用于预防新冠",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "失落的创新药新贵贝达药业: 单品贡献9成营收、毛利率连降，A股失意5年转战港股 盈利能力下降",
            "features": {
                "keywords": [
                    "贝达药业",
                    "创新药",
                    "营收下降",
                    "毛利率降低",
                    "A股转港股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "失落的创新药新贵贝达药业: 单品贡献9成营收、毛利率连降，A股失意5年转战港股 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]